MX2013011096A - Metodos de tratamiento dirigido a degeneracion lobular frontotemporal. - Google Patents

Metodos de tratamiento dirigido a degeneracion lobular frontotemporal.

Info

Publication number
MX2013011096A
MX2013011096A MX2013011096A MX2013011096A MX2013011096A MX 2013011096 A MX2013011096 A MX 2013011096A MX 2013011096 A MX2013011096 A MX 2013011096A MX 2013011096 A MX2013011096 A MX 2013011096A MX 2013011096 A MX2013011096 A MX 2013011096A
Authority
MX
Mexico
Prior art keywords
ftld
frontotemporal lobar
lobar degeneration
targeted
methods
Prior art date
Application number
MX2013011096A
Other languages
English (en)
Spanish (es)
Inventor
Holger Patzke
Gerhard Koenig
Jean-Francois Blain
Original Assignee
Envivo Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Envivo Pharmaceuticals Inc filed Critical Envivo Pharmaceuticals Inc
Publication of MX2013011096A publication Critical patent/MX2013011096A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D267/00Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02Seven-membered rings
    • C07D267/08Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/16Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D267/20[b, f]-condensed
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
MX2013011096A 2011-03-26 2012-03-26 Metodos de tratamiento dirigido a degeneracion lobular frontotemporal. MX2013011096A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161467989P 2011-03-26 2011-03-26
PCT/US2012/030527 WO2012135097A1 (en) 2011-03-26 2012-03-26 Methods of targeted treatment of frontotemporal lobar degeneration

Publications (1)

Publication Number Publication Date
MX2013011096A true MX2013011096A (es) 2014-06-06

Family

ID=45931040

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013011096A MX2013011096A (es) 2011-03-26 2012-03-26 Metodos de tratamiento dirigido a degeneracion lobular frontotemporal.

Country Status (13)

Country Link
US (1) US20140179678A1 (https=)
EP (1) EP2691099A1 (https=)
JP (2) JP5995956B2 (https=)
CN (2) CN103561747B (https=)
AR (1) AR085572A1 (https=)
AU (1) AU2012236852A1 (https=)
CA (1) CA2831291A1 (https=)
IL (1) IL228405A0 (https=)
MX (1) MX2013011096A (https=)
RU (1) RU2013147810A (https=)
TW (1) TW201247205A (https=)
UY (1) UY33973A (https=)
WO (1) WO2012135097A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10149836B2 (en) 2014-03-21 2018-12-11 The Board Of Regents Of The University Of Texas System Isoxazole treatments for frontotemporal dementia
US10189841B2 (en) 2015-11-20 2019-01-29 Forma Therapeutics, Inc. Purinones as ubiquitin-specific protease 1 inhibitors
AR119149A1 (es) * 2019-06-12 2021-11-24 Arkuda Therapeutics Derivados de isoquinolina como moduladores de la progranulina
US20230201269A1 (en) * 2020-04-24 2023-06-29 Spinalcyte, Llc Treatment of frontotemporal dementia using fibroblasts and products thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6723564B2 (en) 1998-05-07 2004-04-20 Sequenom, Inc. IR MALDI mass spectrometry of nucleic acids using liquid matrices
CN101573333B (zh) * 2006-10-28 2013-06-12 梅特希尔基因公司 组蛋白脱乙酰酶抑制剂
US20090291444A1 (en) * 2008-03-31 2009-11-26 Jason Eriksen Methods and materials for detecting and treating dementia
US20110288070A1 (en) * 2008-05-05 2011-11-24 ROGERS Kathryn Methods for treating cognitive disorders using inhibitors of histone deacetylase
WO2009137499A1 (en) * 2008-05-05 2009-11-12 Envivo Pharmaceuticals, Inc. Inhibitors of histone deacetylase

Also Published As

Publication number Publication date
TW201247205A (en) 2012-12-01
JP2014511848A (ja) 2014-05-19
CN103561747A (zh) 2014-02-05
IL228405A0 (en) 2013-12-31
JP5995956B2 (ja) 2016-09-21
EP2691099A1 (en) 2014-02-05
CN105748484A (zh) 2016-07-13
CA2831291A1 (en) 2012-10-04
RU2013147810A (ru) 2015-05-10
US20140179678A1 (en) 2014-06-26
AU2012236852A1 (en) 2013-09-26
CN103561747B (zh) 2016-04-06
WO2012135097A1 (en) 2012-10-04
AR085572A1 (es) 2013-10-09
JP2017019826A (ja) 2017-01-26
UY33973A (es) 2012-10-31
NZ615177A (en) 2016-02-26

Similar Documents

Publication Publication Date Title
EA033067B1 (ru) Способ лечения метаболических расстройств у пациента, имеющего противопоказание к назначению бигуанидного соединения
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
EP4374873A3 (en) Methods for treating or preventing opthalmological conditions
HK1211525A1 (en) Laquinimod and pridopidine for treating neurodegenerative disorders
MY171920A (en) Prevention and treatment of ocular conditions
PH12014501997A1 (en) Esketamine for the treatment of treatment-refractory or treatment-resistant depression
MX2019003249A (es) Diagnostico, prevencion y tratamiento de enfermedades de la articulacion.
EA201590654A1 (ru) Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона
WO2012129112A3 (en) Use of intracellular enzymes for the release of covalently linked bioactives
IN2014CN03123A (https=)
WO2014106825A3 (en) Methods and devices for identifying improper medical reporting
PT2774991T (pt) Sistema de entrega de fármaco para utilização no tratamento ou diagnóstico de distúrbios neurológicos
MX340536B (es) Terapia direccionada al receptor del factor de crecimiento epidermico (egfr).
WO2012142409A3 (en) Diagnostic markers and therapeutic targets of kawasaki disease
PH12014500381A1 (en) Therapeutic methods
WO2013052158A3 (en) Targeted nanovectors and their use for treatment of brain tumors
MX2013011096A (es) Metodos de tratamiento dirigido a degeneracion lobular frontotemporal.
PH12014502065A1 (en) Vesicular formulations
WO2013138338A3 (en) Methods for treating tissue damage associated with ischemia with apoliporotein d
WO2012153253A3 (en) Aromatic compounds and metal complexes thereof
NZ704280A (en) Baclofen and acamprosate based therapy of macular degeneration disorders
WO2013038200A3 (en) Neurodevelopmental disorders
WO2012004416A3 (en) Treatment of a disease associated with retinal degenerative disorder
ZA201306759B (en) Compounds for use in imaging,diagnosing and/or treatment of diseases of the central nervous system
RU2012142334A (ru) Антиагрегационное средство для лечения болезни альцгеймера

Legal Events

Date Code Title Description
FA Abandonment or withdrawal